Corporate | 10 May 2005 07:35

Eckert & Ziegler AG: Increasing Sales of 28% in the Therapy Segment

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Berlin, May 10, 2005. Eckert & Ziegler AG (ISIN DE0005659500), a Berlin-based specialist for radiation related products for the diagnosis and treatment of cancer, increased its sales by 8% to 8.6 million EUR (previous year: 8.0 Mio EUR) in the first quarter. Most of this increase is due to the Therapy segment which grew by 28% to 3.7 million EUR (previous year: 2.9 million EUR), de- spite delays in the delivery of tumor radiation systems. Profit per share de- clined in the first quarter to 0.09 EUR (previous year: 0.14 EUR), mainly due dot missing gross margin. The level of liquid funds and money-like securities remained nearly unchanged throughout the period under period, at 7.1 million EUR. For the financial year 2005 the management expects sales of approxi- mately 40 million EUR and an earning per share between 0,50 and 0,80 EUR. The complete quarterly report I/2005 can be viewed at www.ezag.de. Your contact for enquiries: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, D-13125 Berlin Tel.: +49 (0) 30 / 94 10 84-138 http://www.ezag.de End of announcement (c)DGAP 10.05.2005 —————————————————————————— WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 100735 Mai 05